Leqembi Shows Long-Term Stability in Real-World Alzheimer's Study
Event summary
- 75.9% of Leqembi-treated patients remained stable, 6.6% improved over 17 months in the LEADER study.
- 82.5% of early Alzheimer's patients showed no disease progression across sex, race, and APOE genotypes.
- Nearly 87% of patients chose to continue Leqembi treatment, with consistent safety profiles observed.
- ARIA events occurred in 12.3% of patients, mostly asymptomatic and mild in severity.
The big picture
The LEADER study reinforces Leqembi's role as a cornerstone therapy for early Alzheimer's, with real-world evidence supporting its long-term benefits. Eisai and BioArctic's strategic collaboration continues to drive regulatory momentum, positioning the drug for broader global commercialization. The findings underscore the growing importance of amyloid-targeting treatments in delaying cognitive decline.
What we're watching
- Regulatory Expansion
- Whether Eisai and BioArctic can secure approvals for Leqembi's subcutaneous formulation in key markets like Japan and China.
- Market Penetration
- The pace at which Leqembi adoption accelerates beyond clinical trials into diverse real-world settings.
- Competitive Dynamics
- How sustained efficacy data will position Leqembi against emerging Alzheimer's therapies in development.